An Interleukin-6-Producing Cardiac Myxoma Associated with Mediastinal Lymphadenopathy

Takizawa, Takako; Sumino, Hiroyuki; Kanda, Tsugiyasu; Kobayashi, Isao; Nagai, Ryozo; Ichikawa, Shûichi

doi:10.1159/000006986

Cited by 9 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As shown in the present report, IL-6 from cardiac myxoma can induce several other conditions such as multiple cerebellar hemorrhages, 12 pseudovasculitis, 14 mediastinal lymphadenopathy, 15 and left ventricular hypertrophy. 16 However, there has been no report of cardiac myxoma with plasma cell infiltration, which suggests CD.…”

Section: Discussionsupporting

confidence: 68%

A case of interleukin-6–producing cardiac myxoma resembling multicentric Castleman's disease

Morishima¹,

Marui²,

Shimamoto

et al. 2009

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 68%

A case of interleukin-6–producing cardiac myxoma resembling multicentric Castleman's disease

Morishima¹,

Marui²,

Shimamoto

et al. 2009

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

“…There are several interesting cases of cardiac myxoma complicated by either mediastinal lymphadenopathy or left ventricular hypertrophy. 51,52) These cases may suggest a clinical role for IL-6 in the heart. Interleukin-6 in heart transplantation: Myocardial dysfunction in the donor heart is a common problem and is so severe as to preclude its use for transplantation in 20% of cases.…”

Section: )mentioning

confidence: 92%

Interleukin-6 and Cardiovascular Diseases

2004

Self Cite

View full text Add to dashboard Cite

SUMMARYInflammatory cytokines are important for both cardiovascular scientists and practicing clinicians. Interleukin-6 (IL-6) has been emphasized by reports of elevated circulating as well as intracardiac IL-6 levels in patients with congestive heart failure (CHF). IL-6 may contribute to the progression of myocardial damage and dysfunction in chronic heart failure syndrome resulting from different causes. As the cause of CHF in cardiomyopathy, myocarditis, allograft rejection, and left ventricular assist device (LVADs) conditions, circulating IL-6 levels are associated with the severity of left ventricular dysfunction, and are also strong predictors of subsequent clinical outcomes. Continuous and excessive production of IL-6 promotes myocardial injury by breaking down both cytokine networks and viral clearance under viral myocarditis. Although IL-6 is likely important in the process of viral antigen presentation, early activation of immune responses and attenuation of viral replication also appear to be significant in an animal model of viral myocarditis. IL-6 can cause cardiac hypertrophy through the IL-6 signal transducing receptor component, glycoprotein 130. There are several interesting cases of cardiac myxoma complicated with mediastinal lymphadenopathy or left ventricular hypertrophy. Increased expression of IL-6 is observed in the myocardium of all donor hearts showing marked dysfunction. Myocardial IL-6 concentrations are also significantly higher in LVAD candidates compared with advanced heart failure patients. Although the IL-6 family plays a central role in the pathophysiology of cardiovascular diseases, it remains to be determined whether the IL-6 family is beneficial or detrimental. Future study will be needed to resolve this question. (Jpn Heart J 2004; 45: 183-193)

show abstract

“…Of note, expression of IL-6 also has been observed in some cases of this neoplasm (20,21). EMH in cardiac myxomas thus also could be related to local production of IL-6.…”

Section: Discussionmentioning

confidence: 81%

Hematopoiesis/Erythropoiesis in Myocardial Infarcts

Goldman

Wurzel

2001

Modern Pathology

View full text Add to dashboard Cite

Extramedullary hematopoiesis occurring in the myocardium has previously only been reported in a single case of a neonate with cyanotic congenital heart disease. Herein we report the incidental discovery of extramedullary hematopoiesis or pure erythropoiesis in four failing adult hearts with myocardial infarction. In two cases, extramedullary hematopoiesis or erythropoiesis was identified in cardiectomy specimens removed at orthotopic heart transplantation; in two other cases, erythropoiesis was found in left ventricular tissue removed at the time of implantation of left ventricular assist devices. Myocardial hematopoiesis/ erythropoiesis was identified based on characteristic light-microscopic findings in routinely processed tissue and was confirmed by immunhistochemistry using monoclonal antibodies to the erythroid cell marker glycophorin A (positive in all cases), the megakaryocyte marker CD61, and the granulocyte marker neutrophil elastase (the latter two markers positive in one case only). None of the four patients had a myeloproliferative disorder or evidence of a myelophthisic process. No hematopoietic elements were identified in 109 cardiectomy specimens without acute or recent infarcts. Myocardial hematopoiesis or erythropoiesis could represent heretoforeunrecognized manifestations of altered cytokine expression in patients with heart failure due to myocardial infarction.

show abstract

An Interleukin-6-Producing Cardiac Myxoma Associated with Mediastinal Lymphadenopathy

Cited by 9 publications

References 5 publications

A case of interleukin-6–producing cardiac myxoma resembling multicentric Castleman's disease

A case of interleukin-6–producing cardiac myxoma resembling multicentric Castleman's disease

Interleukin-6 and Cardiovascular Diseases

Hematopoiesis/Erythropoiesis in Myocardial Infarcts

Contact Info

Product

Resources

About